First-of-its-kind maintenance therapy approved for extensive-stage small cell lung cancer, a historically difficult-to-treat malignancy.
A coalition of influential investors is urging shareholders to reject the CEO's new compensation package, citing major governance concerns.
The designation for ALTO-101 targets cognitive impairment, a debilitating aspect of schizophrenia with no currently approved treatments.
H.C. Wainwright more than doubles its price target to $7 as the company delivers its first electrolyzer to a major green hydrogen facility in Portugal.
The U.S. Food and Drug Administration has accepted for review the company's New Drug Application for Relacorilant, a treatment for Cushing's syndrome.
Key approvals for Regeneron, Corcept, and a Fast Track designation for Alto Neuroscience signal a positive regulatory environment.
Analyst sets a new $70 price target, citing strong revenue forecasts and potential for margin expansion for the airline carrier.
Analyst cites a 'stronger for longer' demand cycle for hard disk drives, fueled by the explosive growth of cloud computing and AI.